July 18th 2025
Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during cisplatin therapy.
Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
View More
GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer
View More
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
View More
Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Oncology Town Hall™ 2025 ESMO-GI Congress Highlights: The Latest Data on Immune-Based Strategies Across Hepato...
July 15, 2025
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
2nd Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers
View More
19th Annual New York GU Cancers Congress™
March 13-14, 2026
Register Now!
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
View More
Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer
View More
From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment
View More
Proactive Adverse Event Management for HER2+ BTC Treatments
View More
Heated Chemo During Resection Shows No Benefit in Advanced CRC
July 13th 2018The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis, according to phase III study results presented at the 2018 ASCO Annual Meeting.
Four-Drug Chemo Combo Significantly Improves Pancreatic Cancer Survival
July 9th 2018In a major advance that set a new standard of care for the treatment of patients with resected pancreatic cancer, a modified FOLFIRINOX regimen (mFOLFIRINOX) dramatically improved survival compared with standard gemcitabine as postoperative therapy.
TAS-102 Prolongs Survival in Patients With Advanced Gastric Cancer
July 6th 2018Patients with heavily pretreated metastatic or advanced gastric cancer who received TAS-102 (trifluridine/tipiracil; Lonsurf) saw a significant overall survival benefit, according to phase III study findings presented at the 2018 World Gastrointestinal Cancer Congress.
BLU-667 Shows Clinical Benefit in Advanced, RET-Altered Solid Tumors
April 20th 2018BLU-667 appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies, according to study findings from a phase I clinical trial presented at the AACR Annual Meeting 2018.
Diets Rich in Nuts Improve Survival Rates in Patients with Colon Cancer
April 5th 2018Patients with stage III colon cancer who ate at least 2 servings of nuts per week had superior disease-free survival (DFS) and overall survival (OS), according to results from the CALGB 8903 study published in the Journal of Clinical Oncology.
FDA Grants Priority Review to Nivolumab/Ipilimumab for Subgroup of Patients With Colorectal Cancer
March 27th 2018The FDA has granted a priority review to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.
Clonal Evolution in MSI-H Colorectal Cancer Suggests Repeated Molecular Testing May Be Necessary
February 28th 2018Genetic changes that occur during DNA cloning in people with microsatellite instability-high (MSI-H) colorectal cancer may affect the efficacy of targeted and immunologic therapies. Repeated testing may be necessary to ensure that targeted treatments keep up with the changes in DNA.
Older Patients with Colorectal Cancer Are More Likely to Develop Cardiovascular Disease
February 2nd 2018According to results from an analysis of the Surveillance, Epidemiology, and End Results database of the National Cancer Institute, older adults with colorectal cancer are more likely to develop cardiovascular disease and congestive heart failure.